Awakn Life Sciences Corp
Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavi… Read more
Awakn Life Sciences Corp (AWKNF) - Total Assets
Latest total assets as of October 2024: $668.81K USD
Based on the latest financial reports, Awakn Life Sciences Corp (AWKNF) holds total assets worth $668.81K USD as of October 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Awakn Life Sciences Corp - Total Assets Trend (2021–2024)
This chart illustrates how Awakn Life Sciences Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Awakn Life Sciences Corp - Asset Composition Analysis
Current Asset Composition (January 2024)
Awakn Life Sciences Corp's total assets of $668.81K consist of 91.4% current assets and 8.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 75.0% |
| Accounts Receivable | $20.61K | 3.8% |
| Inventory | $-13.86K | -2.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $46.33K | 8.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Awakn Life Sciences Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Awakn Life Sciences Corp's current assets represent 91.4% of total assets in 2024, an increase from 57.8% in 2021.
- Cash Position: Cash and equivalents constituted 75.0% of total assets in 2024, up from 44.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 8.5% of total assets.
Awakn Life Sciences Corp Competitors by Total Assets
Key competitors of Awakn Life Sciences Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Awakn Life Sciences Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Awakn Life Sciences Corp generates 0.16x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Awakn Life Sciences Corp is currently not profitable relative to its asset base.
Awakn Life Sciences Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.29 | 0.51 | 1.97 |
| Quick Ratio | 0.29 | 0.51 | 1.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.56 Million | $ -999.75K | $ 234.94K |
Awakn Life Sciences Corp - Advanced Valuation Insights
This section examines the relationship between Awakn Life Sciences Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.07 |
| Latest Market Cap to Assets Ratio | 4.37 |
| Asset Growth Rate (YoY) | -87.6% |
| Total Assets | $543.35K |
| Market Capitalization | $2.37 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Awakn Life Sciences Corp's assets at a significant premium ( 4.37x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Awakn Life Sciences Corp's assets decreased by 87.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Awakn Life Sciences Corp (2021–2024)
The table below shows the annual total assets of Awakn Life Sciences Corp from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-01-31 | $543.35K | -87.63% |
| 2023-01-31 | $4.39 Million | -36.10% |
| 2022-01-31 | $6.88 Million | +732.97% |
| 2021-01-31 | $825.49K | -- |